ClinicalTrials.gg
CompletedNCT06743997Updated Apr 17, 2025

A Study to Compare Eutropin Formulations in Healthy Volunteers for Bioavailability, Safety, and Tolerability

A Phase 1 interventional study of Test Drug (Eutropin Catridge, 48IU/Cartridge) and Reference Drug (Eutropin, 4 IU/vial) in Healthy Volunteers, sponsored by LG Chem. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-17.

Sponsored by LG Chem · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
19 Years to 40 Years
Sex
All
01

Study summary

A randomized, Open Label, Single Subcutaneous Dose, 2x2 Crossover Study to Investigate the Relative Bioavailability, Safety and Tolerability among Different Eutropin Formulations in Healthy Volunteers

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

LG Chem is the lead sponsor of 71 studies on the registry; 8 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 1 (8%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged 19 to 40years at screening.
  • Voluntarily decide to participate and provide written .
  • Able to receive the product (IP) and pre-treatment drugs.
  • Wiliing and able to comply with study requirements, including follow-up visits and blood/urine sampling.

Exclusion criteria

Exclusion Criteria:

  • History of conditions contraindicating somatropin or pre-treatment drugs.
  • medical history.
  • Participation in another clinical trial and receipt of an product within 80 days prior to the first IP administration.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Participants receive a single subcutaneous dose of the Test Drug(T), in the first period, followed by a washout period, and then a single subcutaneous dose of the Reference Drug(R) in the second period.

    Drug: Test Drug (Eutropin Catridge, 48IU/Cartridge) · Drug: Reference Drug (Eutropin, 4 IU/vial)

  • Experimental
    Sequence 2

    Participants receive a single subcutaneous dose of the Reference Drug(R), in the first period, followed by a washout period, and then a single subcutaneous dose of the Test Drug(T) in the second period.

    Drug: Test Drug (Eutropin Catridge, 48IU/Cartridge) · Drug: Reference Drug (Eutropin, 4 IU/vial)

Interventions

  • DrugTest Drug (Eutropin Catridge, 48IU/Cartridge)

    Liqid somatropin

    Also known as: T, Test Drug

  • DrugReference Drug (Eutropin, 4 IU/vial)

    Lyophilized somatropin

    Also known as: R, Reference Drug

06

What researchers measure

Primary outcomes

  1. AUClast of somatropin

    AUClast will be used to evaluate the pharmacokinetics of somatropin

    Time frame: 0 to 24 hours post-dose

Secondary outcomes

  1. AUCinf of somatropin

    AUCinf will be used to evaluate the pharmacokinetics of somatropin.

    Time frame: 0 to 24 hours post-dose

  2. Cmax of somatropin

    Cmax will be used to evaluate the pharmacokinetics of somatropin.

    Time frame: 0 to 24 hours post-dose

  3. Tmax of soatropin

    Tmax will be used to evaluate the pharmacokinetics of somatropin.

    Time frame: 0 to 24 hours post-dose

  4. T1/2β of somatropin

    T1/2β will be used to evaluate the pharmacokinetics of somatropin.

    Time frame: 0 to 24 hours post-dose

  5. Change in IGF-1 levels

    Change in IGF-1 levels will be used to evaluate the parmacodynamic effect of somatropin.

    Time frame: 0 to 24 hours post-dose

  6. Change in IGFBP-3 levels

    Change in IGFBP-3 levels will be used to evaluate the parmacodynamic effect of somatropin.

    Time frame: 0 to 24 hours post-dose

07

Study locations

1 site
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Apr 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Dec 20, 2024
StartActual
Jan 13, 2025
Primary completionActual
Apr 15, 2025
CompletionActual
Apr 15, 2025
Last update
Apr 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06743997
Lead sponsor
LG Chem
Responsible party
Sponsor
First posted
Dec 20, 2024
Start date
Jan 13, 2025
Primary completion
Apr 15, 2025
Completion
Apr 15, 2025
Last update
Apr 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion